Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

StereoTactic Radiotherapy for Wet Age-Related Macular Degeneration (STAR): A Randomised, Double-masked, Sham-controlled, Clinical Trial Comparing Low-voltage X-ray Irradiation With as Needed Ranibizumab, to as Needed Ranibizumab Monotherapy.

NCT02243878 is registered in ClinicalTrials.gov with King's College Hospital NHS Trust as lead sponsor.

NCT NCT02243878
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02243878 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
StereoTactic Radiotherapy for Wet Age-Related Macular Degeneration (STAR): A Randomised, Double-masked, Sham-controlled, Clinical Trial Comparing Low-voltage X-ray Irradiation With as Needed Ranibizumab, to as Needed Ranibizumab Monotherapy.
Lead sponsor
King's College Hospital NHS Trust
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2014
Completion date
April 30, 2024
Enrollment
411 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular (wet) age-related macular degeneration (amd)